Tools   Select Another Resource Report Type

http://www.hipsci.org/

A UK national induced pluripotent stem (iPS) cell resource that will create and characterize more than 1000 human iPSCs from healthy and diseased tissue for use in cellular genetic studies. Between 2013 and 2016 they aim to generate iPS cells from over 500 healthy individuals and 500 individuals with genetic disease. They will then use these cells to discover how genomic variation impacts on cellular phenotype and identify new disease mechanisms. Strong links with NHS investigators will ensure that studies on the disease-associated cell lines will be linked to extensive clinical information. Further key features of the project are an open access model of data sharing; engagement of the wider clinical genetics community in selecting patient samples; and provision of dedicated laboratory space for collaborative cell phenotyping and differentiation.

Proper citation: HipSci (RRID:SCR_003909) Copy   

•   Source: SciCrunch Registry

http://www.ibcresearch.org/biobank/

The IBC Research Foundation BioBank is a secure, privacy-protected collection of biological specimens from ibc-diagnosed patients (cases, and, unlike the former George Washington University IBC Registry, ibc patients who have died, those who are under legal age, and those living but unable to make decisions for themselves, may be consented to participate in the IBC Research Foundation BioBank by their authorized representative) and from those not diagnosed with ibc (controls), volunteering following a consent decision making process, and signing an Informed Consent. Clinical Data and a comprehensive questionnaire will also be obtained for those diagnosed with ibc. The Inflammatory Breast Cancer Research Foundation (ibcRF) has established a BioBank and Clinical Database. The BioBank contains non-tumor RNA and DNA, tumor RNA and DNA, blocks and slides from diagnostic pathology, and medical records describing clinical and pathologic findings at diagnosis.

Proper citation: Inflammatory Breast Cancer Biobank (RRID:SCR_004556) Copy   

•   Source: SciCrunch Registry

http://vitiligobiobank.org/

A non-profit collection of biological samples and detailed associated clinical data, designed to facilitate medical research into vitiligo, a devastating skin disease that is much neglected. They collect, store and analyze biological samples throughout the network of collaborators in 11 countries, using standard collection protocols and unified patient record, which are then made available to the scientific community and research organizations investigating pathogeneses, diagnostics, new treatments, and ultimately a cure for vitiligo. The core asset is a large collection of well-organized hair, blood, serum and DNA samples, integrated with comprehensive and anonymized patient records.

Proper citation: Vitiligo Biobank (RRID:SCR_003863) Copy   

•   Source: SciCrunch Registry

http://www.bonebank.com

Bone Bank Allografts is the distributor of the SteriGraft line of high quality bone and soft tissue allografts to medical professionals. The company has been in existence for over 13 years and has helped doctors and their patients with over one hundred thousand successful transplantations. Bone and soft tissue allografts in the SteriGraft line are validated to a sterility assurance level (SAL) of 10(-6) in accordance with ISO 11137-2 Method 1. Bone Bank Allografts was founded in 1993 in response to a growing need for allograft tissue in South Texas. Since 1993, Bone Bank Allografts'' distribution network has grown to cover Texas, the country and the globe, fulfilling surgical needs for allograft tissue in more than 175,000 successful transplantations. Located in San Antonio, Texas, Bone Bank Allografts is dedicated to a just, equitable and fair distribution of cadaveric tissue to surgeons, hospitals, surgicenters and dental offices. Over the years, our customers have come to rely on the superior quality of our tissue products as well as the unmatched service of our well trained, certified Tissue Bank Specialists (CTBS) and our knowledgeable distribution staff. With accreditation from the American Association of Tissue Banks (AATB), registration with the U.S. Food and Drug Administration (FDA) and compliance with the FDA''s Good Tissue Practices, Bone Bank Allografts continues to pursue our mission: To enhance the quality of patient care by providing safe, high quality allograft tissues to health care professionals for transplant and research. Most recently, Bone Bank Allografts has taken the next important step in tissue banking by developing a powerful partnership with Texas Human Biologics (THB) in order to process donated human tissue.

Proper citation: Bone Bank Allografts (RRID:SCR_004432) Copy   

•   Source: SciCrunch Registry

http://www.alsconsortium.org/neals_samples.php

Repository of serum, plasma, cerebrospinal fluid (CSF), whole blood, extracted DNA, and urine samples from NEALS and Massachusetts General Hospital Neurology Clinical Trials Unit (NCTU) research studies of amyotrophic lateral sclerosis (ALS). Samples from this repository are available to researchers for the purpose of furthering the understanding of ALS or developing disease biomarkers. Applications will be accepted at any time, but the committee meets bi-monthly to review applications. The application requires a brief description and scientific justification for the use of the samples. Priority will be given to members of NEALS and investigators from sites that participated in the collection of samples. Investigators must provide IRB approval from their institution. Applications may be submitted to: mghneuroclinicaltrialsunit (at) partners.org (please cc: tlincoln (at) partners.org) NEALS collects an administrative fee of $1,000 at the time of application submission to offset processing costs. If an application for samples is denied, 80% of the administrative fee will be returned. The administrative fee is waived for NEALS members. Checks may be made payable to: The Northeast ALS Consortium.

Proper citation: NEALS Sample Repository (RRID:SCR_004271) Copy   

•   Source: SciCrunch Registry

http://www.geenivaramu.ee/en/

The Estonian Biobank is the population-based biobank of the EGCUT. The project is conducted in accordance with the Estonian Genes Research Act and all participants have signed a broad informed consent form (www.biobank.ee and Metspalu 2004, Drug Dev. Res.). As of December 2011, the biobank contains 51,515 participants (gene donors). The database of genotypic, phenotypic, health and genealogical information represents about 5% of Estonia''s adult population, and is the largest cohort ever gathered in Estonia. The age, sex and geographical distribution of this cohort reflect the structure of the adult population in Estonia. The database enables to conduct research in order to find links between genes, environmental factors, lifestyles and complex diseases or other traits. Active use of the biobank has started and although the first users are researchers all over the world with hundreds of different projects currently underway, industry is also interested. At the international level, the EGCUT will join the BBMRI follow-up program (ERIC) and through this channel provide service (biobanking, genotyping, sequencing and data analysis) for the centers in Europe who need it. Currently, the first follow-up study is underway and the molecular information of the cohort will be increased. For example, we have over 12 000 DNA samples analyzed by high density genotyping arrays and over 10 000 plasma samples analyzed by NMR scans, over 1000 individuals with RNA expression arrays, 2000 individuals with clinical laboratory analysis (over 40 tests) and over 60 full genomes are under deep sequencing. The infrastructure of the EGCUT includes a laboratory for DNA genotyping and next generation sequencing all based on Illumina platforms (HiScanSQ, HiSeq2000 and robotics), an IT unit (databases) with required computing power and storage space (1.2PB), data analysis team (bioinformatics and statistical genetics) and last but not least, a patient recruitment unit (health records, lifestyle and environmental information and biological samples ����?����������?? DNA, plasma and WBC from all 51515 gene donors). This is all located on 1000m2 in a brand new laboratory building, Riia str 23, Tartu, Estonia.

Proper citation: Estonian Genome Center (RRID:SCR_004467) Copy   

•   Source: SciCrunch Registry

http://www.oncoreuk.org/

No longer functioning as an independent charity, onCore UK is a national cancer biobanking organization. Our mission is to serve as an action team that informs, coordinates and develops cancer biobanking to enable research towards the discovery and development of new interventions against cancer. We also offer advice to researchers who need to collect and store samples for their own specific projects. Our main strategic objectives are: * To empower research using human biosamples to find new and effective means of preventing, detecting or treating cancer. * To improve access by researchers to the human biosamples they require for their work. * To facilitate an environment in which patients, the public, health professionals, researchers, funders of research, policy makers and regulators can work together to support cancer biobanking and the research it underpins. * To provide practical information, coordination and development for current and future people and organizations involved in cancer biobanking to ensure that they are not unnecessarily hindered in their work. * To provide an accurate and regularly updated picture of the cancer biobanking provision in the UK that will inform future decisions by funders supporting research using donated human biosamples. * To distribute the human biosamples that onCore UK has in its custody. onCore UK conducts its business within the overall scope of the National Cancer Research Institute (NCRI) and for the benefit of cancer research. In the past we have also worked with selected NHS hospitals in different parts of the country to collect biosamples and relevant clinical data donated by cancer patients. These biosamples are stored in a secure repository and researchers can apply to use them. We make anonymized biosamples and data available for scientifically and ethically approved research on a cost-recovery basis. onCore UK works with other cancer biobanks in the UK via the NCRI Confederation of Cancer Biobanks (CCB), and with other biobanks internationally, to improve access for researchers to larger numbers of high quality biosamples, to harmonize how biobanks work and to share expertise for the benefit of all involved.

Proper citation: onCore UK (RRID:SCR_004348) Copy   

•   Source: SciCrunch Registry

http://bbmri-eric.eu

BBMRI is a pan-European and internationally broadly accessible research infrastructure and a network of existing and de novo biobanks and biomolecular resources. The infrastructure will include samples from patients and healthy persons, representing different European populations (with links to epidemiological and health care information), molecular genomic resources and biocomputational tools to optimally exploit this resource for global biomedical research. During the past 3 years BBMRI has grown into a 53-member consortium with over 280 associated organizations (largely biobanks) from over 30 countries, making it the largest research infrastructure project in Europe. During the preparatory phase the concept of a functional pan-European biobank was formulated and has now been presented to Member States of the European Union and for associated states for approval and funding. BBMRI will form an interface between specimens and data (from patients and European populations) and top-level biological and medical research. This can only be achieved through a distributed research infrastructure with operational units in all participating Member States. BBMRI will be implemented under the ERIC (European Research Infrastructure Consortium) legal entity. BBMRI-ERIC foresees headquarters (central coordination) in Graz, Austria, responsible for coordination of the activities of National Nodes established in participating countries. BBMRI is in the process of submitting its application to the European Commission for a legal status under the ERIC regulation, with an expected start date at the end of 2011. Major synergism, gain of statistical power and economy of scale will be achieved by interlinking, standardizing and harmonizing - sometimes even just cross-referencing - a large variety of well-qualified, up-to date, existing and de novo national resources. The network should cover (1) major European biobanks with blood, serum, tissue or other biological samples, (2) molecular methods resource centers for human and model organisms of biomedical relevance, (3) and biocomputing centers to ensure that databases of samples in the repositories are dynamically linked to existing databases and to scientific literature as well as to statistical expertise. Catalog of European Biobanks www.bbmriportal.eu Username: guest / Password: catalogue The catalogue is intended to be used as a reference for scientists seeking information about biological samples and data suitable for their research. The BBMRI catalogue of European Biobanks provides a high-level description of Europe''s biobanks characteristics using a portal solution managing metadata and aggregate data of biobanks. The catalogue can be queried by country, by biobank, by ICD-groups, by specimen types, by specific strengths, by funding and more. A search function is available for all data.

Proper citation: Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) (RRID:SCR_004226) Copy   

•   Source: SciCrunch Registry

http://www.partners.org/researchcores/clinical/specimen_BWH.html

The Crimson Biospecimen Core prospectively collects discarded clinical materials matching investigator-defined criteria. Queries are run against real-time data on recently received clinical samples, including ICD.9 codes and results of clinical laboratory testing. Studies using the core must either (1) have an IRB-approved protocol for discarded clinical materials and anonymized information or (2) a protocol to allow collection of discarded samples from patients consented for their study. Collected samples may be additionally processed, aliquotted, or tested per the menu of tests available within the BWH and MGH Clinical Laboratories and Partners Genomics Center. Services: * Collection of discarded clinical specimens including serum, plasma, CSF, urine and microbiological isolates for IRB-approved studies. * Processing or additional clinical testing of collected materials. * Ability to receive consented patient samples for processing and clinical testing. * Online interface to manage collected sample inventories, associated test results, and study users/workgroup per IRB-approval.

Proper citation: Crimson Biospecimen Core (RRID:SCR_004451) Copy   

•   Source: SciCrunch Registry

http://www.biomax.us/

Our robust searchable Tissue Bank database at US Biomax contains normal, non-cancerous disease and cancer samples, just a fraction of total paraffin tissue bank. Use advanced search function to define your search. Some of them have H&E images. Our tissue repository, tissue bank has huge paraffin tissue blocks, a large selection of histology tissue section slides of human cancer, normal tissue, rhesus and cynomolgus normal fresh frozen tissue as well as paraffin blocks and slides. It has also normal human organs in paraffin embedded tissue blocks as well as rhesus and cynomolgus monkey normal organ tissues. Snap frozen (fresh frozen) tissue of rhesus/cynomolgus monkey are also available. We also provide tissue array, custom tissue microarray (with samples you provided or from our tissue bank) as well as OEM services. Other products/services available include tissue microarray, paraffin tissue sections, histology services and quantitative telomerase detection kit.

Proper citation: US Biomax (RRID:SCR_004295) Copy   

•   Source: SciCrunch Registry

http://www.uthouston.edu/uth-big/Projects/BioBank.htm

The University of Texas Health Science Center at Houston (UTHealth) Clinical and Translational Sciences (CCTS) BioBank employs a federated rather than a centralized model which encourages participation by sample owners who are concerned about guaranteeing their ownership of samples and sample information about patients, samples and related clinical data. In a federated model, individual sites agree on shared policies and procedures for data and sample sharing and oversight. Samples remain with and are governed by the contributing principal investigator at each site. The contributing investigator has final authority whether or not to collaborate or to release samples to qualified researchers. The goal of SLED (Sample Location and Enhanced Distribution) is to help researchers overcome two of the biggest obstacles preventing their research from beginning: 1) location of samples and related data, and 2) requesting of samples and related data. Prior to SLED''s inception the existing system was limited to providing links to samples and data and relying on phone calls to sample owners to facilitate sharing. Collaboration between the CTSA Biobank Consortium and the informatics team at the University of Texas School of Biomedical Informatics is ongoing during this effort. The initial design was constructed using best practices offered by NIH, NCI, and other biobank industry leaders to support and to improve synergy and interaction among various research efforts. Through SLED, researchers will be able to search for samples using a variety of criteria including availability, clinical data, consent criteria, patient demographics, patient diagnoses, study data, and sample type at local and national biobank sites.

Proper citation: UTHealth BioBank (RRID:SCR_004570) Copy   

•   Source: SciCrunch Registry

http://www.acceleratedcure.org/impact/repository

A repository of biological samples and data from people with multiple sclerosis, selected other demyelinating diseases, and unaffected controls. The repository not only provides much-needed samples and data to researchers studying MS and other diseases, but also aggregates the results from all of these studies so that they can be analyzed collectively, leading to new findings and breakthroughs. The repository collects blood, DNA, and imaging once per year. The repository currently includes samples and data from over 2,700 subjects with Multiple Sclerosis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis, Optic Neuritis, and Clinically Isolated Syndromes, as well as controls. Blood samples are provided as aliquots as serum, plasma, DNA, RNA, and lymphocytes and each sample is accompanied by more than 40 pages of clinical and epidemiological data contributed by the subject and the enrolling neurologist.

Proper citation: Accelerated Cure Project MS Repository (RRID:SCR_004208) Copy   

•   Source: SciCrunch Registry

http://www.medunigraz.at/en/biobank

Biobank Graz is a non-profit central Medical University of Graz (MUG) service facility that provides the logistics and infrastructure to optimally support MUG research teams in the collection, processing and storage of biological samples and their associated data. In the course of this, special attention is given to sample and data quality and to the protection of the individual rights of patients. Samples from selected patients at the Graz LKH-University Clinical Centre, who have signed an informed consent declaration, are deposited in Biobank Graz. This means that excess tissue and blood samples are collected and placed in storage. The samples are harvested in the course of routine interventions undertaken by the different departments and institutes of the Graz LKH-University Clinical Centre and approved for use in research projects only after the completion of all necessary laboratory and histopathological analyses. No additional material is removed: in other words, there are no associated drawbacks whatsoever for the patients involved. Biobank Graz operates a quality management system according to ISO 9001:2008 and offers the following services for the processing and storage of biological samples and the handling of data: * Consistently high sample quality through the processing of samples using standardized methods in accordance with written working instructions (SOPs) * Efficient use of resources through the building of shared infrastructure and the development of optimized processes * A high degree of reliability provided by the storage of samples in 24/7 - monitored storage systems. * Processing and storage of all data in accordance with data protection legislation. Biobank Graz comprises both population-based and disease-focused collections of biological materials. It currently contains approx. 3.8 mio samples from approx. 1.2 mio patients representing a nonselected patient group characteristic of central Europe. Because the Institute of Pathology was, until 2003, the exclusive pathology service provider for major parts of the province of Styria, including its capital Graz (population approx. 1.2 mio people), samples from all human diseases, treated by surgery or diagnosed by biopsy, are included in the collection at their natural frequency of occurrence and thus represent cancers and non-cancerous diseases from all organs, and from all age groups. The scientific value of the existing tissue collection is, thus, not only determined by its size and technical homogeneity (all samples have been processed in a single institute under constant conditions for more than 20 years), but also by its population-based character. These features provide ideal opportunities for epidemiological studies and allow the validation of biomarkers for the identification of specific diseases and determination of their response to treatment. Prospectively collected tissues, blood samples and clinical data comprise, on the one hand, randomly selected samples from all diseases and patient groups to provide sufficient numbers of samples for the evaluation of the disease-specificity of any gene or biomarker. On the other hand, Biobank Graz adopts a disease-focused approach for selected diseases (such as breast, colon and liver cancers as well as some metabolic diseases) through the collection of a range of different human biological samples of highest quality and detailed clinical follow-up data. Graz Medical University established the Biobank to provide improved and sustainable access to biological samples and related (clinical) data both for its own academic research and for external research projects of academic and industrial partners. It is a major interest of the university to initiate co-operative research projects. Biological samples and data are available to external institutions performing high-quality research projects which comply with the Biobank''s ethical and legal framework according to the access rules (Contact: COO Karine Sargsyan, MD, PhD).

Proper citation: Biobank Graz (RRID:SCR_004245) Copy   

•   Source: SciCrunch Registry

http://www3.marshfieldclinic.org/chg/pages/default.aspx?page=chg_pers_med_res_prj

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023. A large collection of biological samples and health information collected for the Personalized Medicine Research Project (PMRP) for use in biological research. Genetic information from 20,000 participants forms a database enabling scientists to study which genes cause disease, which genes predict reactions to drugs, and how environment and genes work together to cause disease. The goal of this project is to learn how to apply genetic science to human health. This knowledge will help researchers develop new medications and diagnostic tests, and will enable physicians to prescribe medications that work best for a particular person. Marshfield Clinic Personalized Medicine Research Project (PMRP) resources currently available: DNA, plasma, serum, questionnaire, electronic medical records to construct phenotypes; ability to recontact subjects for additional information (where they have given consent for recontact); stored pathology specimens collected for clinical purposes; 51 clinically relevant polymorphisms; Illumina 660 quad for ~4200 subjects aged 50+.

Proper citation: Marshfield Clinic Biobank (RRID:SCR_004368) Copy   

•   Source: SciCrunch Registry

https://eyegene.nih.gov

National network of research laboratories for genetic testing of eye disease. They offer testing for affected individuals coupled to registry of clinical information available through patient registry. Large data set for investigators to identify additional genetic risk factors and to explore relationship between genetic disease (genotype) and its clinical manifestation (phenotype).

Proper citation: eyeGENE (RRID:SCR_004523) Copy   

•   Source: SciCrunch Registry

http://www.agre.org/index.cfm

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. A private repository of clinical and genetic information on families with autism. Genetic and clinical data are obtained from families that have more than one family member diagnosed with an Autism Spectrum Disorder. The biological samples, along with the accompanying clinical data, are made available to AGRE-approved researchers worldwide. As they become available, additional family pedigrees will be posted in the online catalog. Cell lines have been established for the majority of families in this collection and serum/plasma is available on a subset of the subjects until stocks are depleted. The diagnosis of autism has been made using the standard Autism Diagnostic Interview-Revised (ADI-R) algorithm and the Autism Diagnostic Observation Scale (ADOS-G). Detailed birth and medical histories (including basic dysmorphology assessments) on children as well as family and medical information for parents and unaffected siblings, are available for nearly all families. DNA, cell lines, serum, plasma and clinical information are made available to AGRE-approved researchers for analysis.

Proper citation: Autism Genetic Resource Exchange (RRID:SCR_004403) Copy   

•   Source: SciCrunch Registry

http://genomics.ucsf.edu/dna-bank

The DNA Bank accepts the clinical samples from projects that have been approved by the Committee on Human Research (CHR). Genomic DNA isolation is performed utilizing standardized and quality controlled Gentra Systems'' PureGene DNA isolation system or Qiagen Kits. The quantity and quality of the genomic DNA isolate is determined by 260/280 UV spectrophotometery. Following isolation and quality assessment, DNA can be aliquoted into a normalized concentration. The preparation of aliquots serves to allow ready distribution of DNA samples to both the client laboratory and their collaborators and to preclude excessive routine freezing and thawing of the primary DNA isolate, a practice which is well known to result in notable degradation of genomic DNA stocks. All samples are stored in alarmed Revco ultra-low freezers at -80����?����?����?��������C. All of the ultra-low freezer units utilized by the DNA Bank are monitored by a temperature sensitive alarm system that provides 24 hour oversight. In the event of a power outage, all freezers are on an emergency back-up electrical generator.

Proper citation: UCSF DNA Bank (RRID:SCR_004248) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10

Open resource of biological samples (DNA, cell lines, and other biospecimens) and corresponding phenotypic data to promote neurological research. Samples from more than 34,000 unique individuals with cerebrovascular disease, dystonia, epilepsy, Huntington's Disease, motor neuron disease, Parkinsonism, and Tourette Syndrome, as well as controls (population control and unaffected relatives) have been collected. The mission of the NINDS Repository is to provide 1) genetics support for scientists investigating pathogenesis in the central and peripheral nervous systems through submissions and distribution; 2) information support for patients, families, and advocates concerned with the living-side of neurological disease and stroke.

Proper citation: NINDS Repository (RRID:SCR_004520) Copy   

•   Source: SciCrunch Registry

http://epi.helmholtz-muenchen.de/kora-gen/index_e.php

KORA-gen is infrastructure to provide phenotypes, genotypes and biosamples for collaborative genetic epidemiological research. From all four surveys that have been conducted so far, the following biological material is on hand: genomic DNA, blood serum, blood plasma and EBV immortalized cell lines (form KORA S4 only). These have been extracted from blood samples and are stored in nitrogen tanks and -80 degrees C refrigerators. Genomic DNA from more than 18.000 adult subjects from Augsburg and the surrounding counties is available at present. So far, EBV immortalized cell lines from 1.600 participants are cultivated. To meet the manifold demands of researchers with genetic and molecular questions KORA-gen fulfills the following prerequisites for successful genetic-epidemiological research: * representative samples from the general population, * well characterized disease phenotypes and intermediate phenotypes, * information on environmental factors, * availability of genomic DNA, serum, plasma and urine, as well as EBV immortalized cell lines. In total, four population based health surveys have been conducted between 1984 and 2000 with 18000 participants in the age range of 25 to 74 years, and a biological specimen bank was established in order to enable scientists to perform epidemiologic research with respect to molecular and genetic questions. The KORA study center conducts regular follow-up investigations and has collected a wealth of information on sociodemography, general medical history, environmental factors, smoking, nutrition, alcohol consumption, and various laboratory parameters. This unique resource will be increased further by follow-up studies of the cohort. The assessment of statistical questions covers the definition of the study design and the calculation of statistical power. Furthermore, we offer assistance in data analysis. Kora-gen can be used by external partners. Interested parties can inform themselves interactively via internet about the available data and rules of access. The genotypic data base is a common resource to all partners.

Proper citation: KORA-gen (RRID:SCR_004510) Copy   

•   Source: SciCrunch Registry

http://dbmi.mc.vanderbilt.edu/research/dnadatabank.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. BioVU is a research resource providing a View into biology at the level of DNA and other important macromolecules. BioVU has two major components. The first is a repository of DNA samples (extracted from discarded blood samples) that are coded solely by a Research Unique Identifier (RUI) derived from the Medical Record Number (MRN) using a one-way hash function. This is a computer algorithm that creates a transformation of each MRN such that the resulting RUI (which is in this instance is a 512 byte identifier) is unique, and has the property that it is not possible to infer or compute the MRN that generated it. As of early 2009, over 50,000 DNA samples were in the biobank, with new samples being added at the rate of approximately 700 per week. The second component of the resource is the creation of a database known as the Synthetic Derivative which is a collection of de-identified information extracted from VUMC''s electronic clinical information systems, indexed by the same one-way RUI used to track samples, and with content changed by deletion or permutation of all identifiers contained within each record. The Synthetic Derivative search interface is available to Vanderbilt researchers via the StarBRITE research portal created and maintained by the Vanderbilt Institute for Clinical and Translational Research. This user interface enables investigators meeting protocol approval criteria and other user agreement requirements to receive protocol-specific sets of data derived from DNA samples and from the Synthetic Derivative., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Vanderbilt BioVU (RRID:SCR_004632) Copy   

•   Source: SciCrunch Registry